Free birth, death registration offered for 7 years
The Punjab government has enacted new rules to streamline and simplify the registration of births and deaths across the province, eliminating fees for timely registrations and easing procedural hurdles for delayed entries.
The Punjab Local Government and Community Development Department has notified the Birth and Death Registration Rules, 2025, following approval from the secretaries of law and local government.
Under the new rules, birth and death registrations within seven years of the event will be processed free of charge, and citizens will also be issued computerised certificates. According to the notification, the registration and issuance of birth or death certificates will remain free of charge for one year.
However, a fee of Rs200 will apply for late registration of births after seven years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
2 days ago
- Express Tribune
Gandapur orders probe into Swat river tragedy
A rescue worker rows a raft while searching for survivors, after tourists, who were on a picnic, were swept away by overflowing floodwaters in the Swat River, in Swat Valley in Pakistan June 27, 2025. Photo: Reuters Khyber-Pakhtunkhwa Chief Minister Ali Amin Gandapur has announced that a high-level committee has been formed to investigate the recent Swat tragedy, in which 14 people drowned in the Swat River. Speaking to the media after a court appearance at the Peshawar High Court, the chief minister said that anyone found negligent in the incident will not be spared. "The tragedy in the Swat River is extremely unfortunate. A committee has been constituted to probe the incident and is actively working. Those responsible for negligence or carelessness will be held accountable once the committee presents its report," Gandapur stated. He added that an indiscriminate anti-encroachment operation is underway across the province, particularly along the banks of the Swat River. "No one is above the lawillegal structures, no matter who they belong to, will be demolished," he asserted. Referring to Governor Faisal Karim Kundi, the chief minister launched a scathing attack, saying, "He can't even win a councillor's seat ... how can he overthrow our government?" The chief minister reaffirmed his government's commitment to removing encroachments without any discrimination and said that similar operations would be launched wherever illegal constructions are found in the province. Meanwhile, a high-level delegation of the Polio Oversight Board (POB), led by Dr Christopher Elias, called on Chief Minister Gandapur in Islamabad to review and reinforce anti-polio efforts in the province. The delegation included representatives from the World Health Organization (WHO), UNICEF, Rotary International, and other global partner organizations. Also present were Prime Minister's Focal Person for Polio Eradication Ayesha Farooq, and senior officials from the National and Provincial Emergency Operation Centers. During the meeting, the participants reviewed the province's ongoing polio eradication efforts and agreed on further streamlining and strengthening strategies to eliminate the poliovirus from Khyber-Pakhtunkhwa. Chief Minister expressed gratitude for the continued support of international partners and reaffirmed his government's commitment to eradicating polio. "The fight against polio is not just a provincial issue but a national and global responsibility," he said. He noted that the provincial government is taking special measures to bolster the immunization program and has begun customizing anti-polio campaigns to fit the unique needs of each district. "Our strategy now involves local solutions to local challenges," he said. To enhance the outreach and acceptance of polio campaigns, Gandapur said elected representatives and religious scholars are being actively involved. He urged local leaders and clerics to help dispel misconceptions and boost public trust in vaccination efforts.
Business Recorder
4 days ago
- Business Recorder
India's Sigachi factory fire death toll rises to 39; cause still unknown
HYDERABAD: The death toll from the explosion and fire at Sigachi Industries' chemical factory in southern India has risen to at least 39, officials said on Tuesday, forcing the supplier of pharma products to shut operations for 90 days. The government of Telangana state, where the facility is located, has formed a five-member committee to probe the incident, the cause of which is yet to be disclosed by the company. The explosion on Monday also injured 34, according to officials. 'We are still clearing the debris,' GV Narayana Rao, director of the Telangana fire disaster response service, told Reuters, adding that the building had completely collapsed. 'Once we are all done with the clearing, only then we will be able to assess if any other body is still remaining under the debris or if it is all clear,' Rao said. Police officials said more than 140 people were working in the plant when the incident occurred. Twenty-five of the deceased were yet to be identified, district administrative official P. Pravinya said. 'I came out (of the plant) to use the restroom and heard a loud blast. It sounded like a bomb blast. I came out and saw fire. A part of the fire also spread towards me. I jumped the wall and escaped,' Chandan Gound, 32, who has been working at the factory for six months, told Reuters by phone. 'Many of them (those inside) managed to escape, but a large number were trapped and could not come out,' Gound added. Sigachi, which makes microcrystalline cellulose (MCC), caters to clients in the pharma, food, cosmetic and specialty chemicals sectors in countries ranging from the U.S. to Australia. MCC's compressibility, binding properties, and ability to boost drug release make it a vital ingredient in pharmaceutical manufacturing. It is also used to prevent the formation of lumps in food products, to maintain texture of cosmetic products, and as a fat substitute in low-calorie foods. Sigachi's Telangana plant contributes a little over a fourth of its total capacity of 21,700 million metric tons per annum. Its shares dropped about 8% on Tuesday and were headed for their sharpest two-day drop on record. Sigachi halted operations at the plant for 90 days from Monday citing damage to equipment and structures. The plant is fully insured and the company is initiating claims. In a separate incident on Tuesday, five people were killed and four others injured in a massive fire at a crackers factory in the Sivakasi manufacturing cluster in the southern Tamil Nadu state, a fire department official said. The incident is the latest in a series of fire accidents in the area.
Express Tribune
6 days ago
- Express Tribune
'The Wild West' of weight loss
In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer. Each week the mother of two injects herself with weight-loss drugs, two of which are in clinical trials and not yet approved for sale by the US Food and Drug Administration. One comes mixed with tirzepatide, the active ingredient in Eli Lilly's Zepbound. Spencer, 50, is not part of any drug trial but mixes the cocktails herself, using tiny doses that she believes are safe. The total cost is about $50 monthly, as little as one-tenth of what she would expect to pay their makers for full treatment. The drugs – glucagon-like peptide-1 (GLP-1) weight-loss medicines – are manufactured and shipped from China, according to the packaging. She orders them through online vendors. Spencer belongs to a fast-growing group of Americans turning to what many call the "grey market" for obesity medicines, bringing cheap active ingredients from China often labelled as for research purposes, according to import data and social media postings. It's a trend that drugmakers Lilly and Novo Nordisk, which makes Wegovy, say is dangerous as well as illicit. Reuters tracked online forums and interviewed seven people who said they bought obesity medicines through this market, including an attorney in Arizona who works for a state insurance agency, a retired nurse in Illinois and a Type 1 diabetic in Louisiana, who said the medicine helped cut her insulin intake by more than half. For more than a year there has been demand for cheap Chinese-made powders, exacerbated by limited health insurance coverage in the US Buyers told Reuters the grey market received a boost from an FDA ruling last year that US compounding pharmacies – outsourcing facilities that create drugs in shortage – must stop selling obesity medicines more cheaply than the companies that developed them. Risky business Shipments of such active ingredients from Chinese entities not registered with the FDA jumped by 44 per cent in January from the previous month, according to research by the Partnership for Safe Medicines, a public health group focused on the safety of prescription drugs. It said its findings are likely an undercount, because unregistered vendors may not disclose that their parcels contain medicines. Packages valued at less than $800 that enter the US under the de minimis rule are not included in the data. Nearly three-quarters of US adults are overweight or obese, according to government estimates, but a survey by nonprofit health policy research organisation KFF found only about 8 per cent say they have taken medicine for weight loss. Most of the grey market buyers Reuters interviewed had told their medical providers they were taking GLP-1 medicines but not where or how they bought them. Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to consulting firm Mercer. Many Americans have paid out of pocket for cheaper compounded drugs. Interest in taking small doses of the drugs has also spurred the online marketplace, buyers said. Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny. They swap advice for navigating the market, exchanging information on vendors, shipping and dosage, and sometimes clubbing together to cover the cost of testing the powders. One forum is called StairwayToGray. It has more than 21,000 members on Telegram and recently was gaining nearly 1,000 members weekly. It did not respond to Reuters' inquiries, and blocked access to the forum after receiving them. It has a website where it says it does not facilitate group purchases. "This community is filling the gaps and being our own regulators, ensuring testing and access for everyone who needs it. Because you shouldn't have to choose between your health or your wallet," it says. Spencer stores her stocks in her fridge and makes them up in the kitchen – carefully measuring sterile water, rolling the vial between her fingers until the powder dissolves, and drawing the liquid into a syringe before injecting it into her thigh or belly. She has lost 24 pounds. "This is working so well for me. It's so easy. It's cheap," said Spencer, who assumes her health plan wouldn't cover the drugs. "I don't know what I would do without this medicine." 'Very dangerous' In February, 38 US state and territory attorney generals wrote the FDA seeking action against illegally sold weight-loss medicines, including "research purposes only" ingredients from China. "Much like with counterfeit versions, these active ingredients come from unregulated, undisclosed sources ... and pose risks of contamination and inclusion of foreign substances," they said. Shabbir Safdar, executive director of the Partnership for Safe Medicines, said unapproved drugs can have problems with sterility, purity and consistency. "It can be very dangerous. You're playing the role of your own doctor, pharmacist, and FDA inspector," he said. Of those interviewed, only Spencer reported any problems: She once got her math wrong and overdosed, resulting in several days of severe flu-like symptoms. Lilly said it had taken many steps to address patient safety risks posed by the proliferation of unsafe or untested tirzepatide. The company said it is filing lawsuits, educating consumers and working with social media companies to identify and remove posts that promote unsafe products, including those described as "research use only." "We will continue to take action to stop those who threaten patient safety and urgently call on regulators and law enforcement to do the same," a Lilly spokesperson told Reuters. Novo Nordisk also said it continues to take action against entities that violate laws and regulations and put patient safety at risk. America's Poison Control agency, which maintains the nation's poison data surveillance system and monitors GLP-1 exposures, said it could not reliably track cases involving unregulated "research chemical powders" because they are sold under various names and formulations. Reuters
